KLDO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KLDO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kaleido Biosciences's interest expense for the three months ended in Dec. 2021 was $ -0.72 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2021 was $-2.84 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kaleido Biosciences's Operating Income for the three months ended in Dec. 2021 was $ -19.70 Mil. Kaleido Biosciences's Interest Expense for the three months ended in Dec. 2021 was $ -0.72 Mil. Kaleido Biosciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Kaleido Biosciences's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaleido Biosciences Annual Data | |||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||
Interest Expense | Get a 7-Day Free Trial | -0.44 | -1.01 | -0.98 | -2.80 | -2.84 |
Kaleido Biosciences Quarterly Data | |||||||||||||||||||
Dec16 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | |
Interest Expense | Get a 7-Day Free Trial | -0.72 | -0.71 | -0.71 | -0.71 | -0.72 |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaleido Biosciences (OTCPK:KLDO) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Kaleido Biosciences's Interest Expense for the three months ended in Dec. 2021 was $-0.72 Mil. Its Operating Income for the three months ended in Dec. 2021 was $-19.70 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2021 was $5.55 Mil.
Kaleido Biosciences's Interest Coverage for the quarter that ended in Dec. 2021 is calculated as
Kaleido Biosciences did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Alison S Long | officer: Chief Medical Officer | KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421 |
Van Hylckama Vlieg Johan | officer: Chief Scientific Officer | C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421 |
Flagship Ventures Fund Iv, L.p. | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Daniel L Menichella | director, officer: Chief Executive Officer | 79 TW ALEXANDER DRIVE, 4101 RESEARCH COMMONS, RESEARCH TRIANGLE PARK NC 27709 |
Kyriazi Theo Melas | director | 2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8 |
Nutritional Health Ltp Fund General Partner Llc | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Nutritional Health Ltp Fund, L.p. | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Anne Prener | director | C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139 |
William E. Duke | officer: CHIEF FINANCIAL OFFICER | C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807 |
Richard William Scalzo | officer: Principal Accounting Officer | 25 ALBERTA LANE, HOLLISTON MA 01746 |
Jean K Mixer | director | C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843 |
Jerald Korn | officer: General Counsel | 128 GORDON RD, NEWTON MA 02468 |
Flagship Ventures Fund V, L.p. | 10 percent owner | ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142 |
Michael W Bonney | director, officer: Executive Chair | 65 HAYDEN AVE, LEXINGTON MA 02421 |
Flagship Venturelabs V Manager Llc | 10 percent owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
From GuruFocus
By Marketwired Marketwired • 10-05-2021
By GlobeNewswire GlobeNewswire • 01-21-2022
By Marketwired Marketwired • 08-09-2021
By Marketwired Marketwired • 08-06-2021
By Marketwired Marketwired • 11-02-2020
By Marketwired Marketwired • 09-02-2021
By Don Li2 Don Li2 • 11-15-2021
By Marketwired Marketwired • 08-10-2021
By Marketwired Marketwired • 02-04-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.